Direct factor Xa inhibitors, such as rivaroxaban, apixaban, edoxaban (factor Xa inhibitors), and direct thrombin inhibitors such as dabigatran are direct oral anticoagulants (DOACs) or non-vitamin K antagonist oral anticoagulants (NOACs) used for secondary prophylaxes in atrial fibrillation and treatment of deep venous thrombosis (DVT) and venous thromboembolism (VTE). The gene discussed is F10; the disease is deep vein thrombosis.